NCT02121639View on ClinicalTrials.gov

Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

January 29, 2014

Primary Completion Date

October 8, 2020

Study Completion Date

September 13, 2021

Conditions
Prostate Cancer
Interventions
DRUG

Placebo

DRUG

AZD5363

Trial Locations (1)

SO16 6YD

Southampton General Hospital, Southampton

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Cancer Research UK

OTHER

lead

University Hospital Southampton NHS Foundation Trust

OTHER